Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
0.85% $0.775
America/New_York / 7 sep 2023 @ 15:59
FUNDAMENTALS | |
---|---|
MarketCap: | 7.25 mill |
EPS: | -10.14 |
P/E: | -0.0764 |
Earnings Date: | Nov 12, 2023 |
SharesOutstanding: | 9.36 mill |
Avg Daily Volume: | 3.11 mill |
RATING 2023-10-03 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Neutral | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0764 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.00x |
Company: PE -0.0764 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.434 - 0.814 ( +/- 30.44%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-23 | Dorbin John W. Jr. | Buy | 70 000 | Employee Stock Option (right to buy) |
2023-10-23 | Dorbin John W. Jr. | Buy | 0 | |
2023-10-16 | Cohen Seth | Buy | 151 416 | Employee Stock Option (right to buy) |
2023-10-16 | Cohen Seth | Buy | 0 | |
2023-09-15 | Versi Ebrahim | Buy | 729 200 | Common Stock |
INSIDER POWER |
---|
92.98 |
Last 88 transactions |
Buy: 1 947 813 | Sell: 1 308 563 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.775 (0.85% ) |
Volume | 0.119 mill |
Avg. Vol. | 3.11 mill |
% of Avg. Vol | 3.84 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.